Related Experiment Videos
Statins, platelet aggregation and coronary heart disease
Esam Z Dajani1, Thomas G Shahwan, Noura E Dajani
1International Drug Development Consultants Corp., 1549 RFD, Long Grove, IL 60047-9532, USA. EsamD@aol.com
Insights
Statins, beyond lowering cholesterol, may prevent heart attacks and strokes by inhibiting platelet aggregation. Pravastatin reduced platelet activation markers and LDL-C in a study, suggesting a potential antithrombotic effect.
Area of Science:
- Cardiovascular Pharmacology
- Hematology
- Biochemistry
Background:
- Statins (HMG-Co-A reductase inhibitors) reduce cardiovascular events through lipid-lowering and non-lipid mechanisms.
- Non-lipid effects include plaque stabilization, endothelial normalization, anti-inflammatory actions, and inhibition of platelet thrombus formation.
- The antiplatelet effects of statins require further investigation due to contradictory findings.
Purpose of the Study:
- To review the effects of statins on platelet aggregation using novel measurement techniques.
- To discuss findings on pravastatin's impact on platelet function and LDL-C in hypercholesterolemic patients.
Main Methods:
- Review of studies on statins and platelet function, focusing on methods by Ma et al.
- Evaluation of pravastatin's effect on adenosine diphosphate (ADP)-induced platelet aggregation, thromboxane B2 (TXB2), and GMP-140 expression.
- Assessment of low-density lipoprotein-cholesterol (LDL-C) levels.
Main Results:
- Pravastatin treatment significantly reduced LDL-C levels.
- Pravastatin inhibited ADP-induced platelet aggregation, TXB2 synthesis, and GMP-140 expression.
- These effects suggest a reduction in factors contributing to thrombus formation.
Conclusions:
- Statins may possess antiplatelet properties independent of their cholesterol-lowering effects.
- Further research with dose-response studies is needed to confirm statin's antiplatelet efficacy.
- Investigating the independence of antiplatelet effects from hypocholesterolemic action could lead to new antithrombotic drugs.
Abstract:
It is becoming increasingly recognized that the beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co-A) reductase inhibitors (statins) on reducing clinically important cardiovascular events (myocardial infarction and stroke) are not only attributable to their hypocholesterolemic effect but also to non-lipid mechanisms of action. The nonlipid factors may include the stabilization of arterial plaques, endothelial normalization, anti-inflammatory effects and inhibition of platelet thrombus formation. The inhibition of platelet thrombus formation has not been adequately studied in man and the results are often contradictory. It is the objective of this review to discuss the effects of statins on platelet aggregation in the context of relatively new and specific techniques for the measurement of platelet function as reported by Ma and coinvestigators in this issue of JAAMP. Ma et al. examined the effect of pravastatin given for 8 to 12 weeks on platelet function and low density lipoprotein-cholesterol (LDL-C) in 21 Chinese patients with primary hypercholesterolemia. Platelet function was evaluated by adenosine diphosphate (ADP)-induced aggregation, thromboxane B2 (TXB2) and the expression of alpha granule membrane protein-140 (GMP-140). GMP-140 is considered one of the most sensitive indicators of the state of platelet function. As expected, pravastatin treatment significantly reduced LDL-C and inhibited ADP-induced platelet aggregation, TXB2 synthesis and the expression of GMP-140--all such parameters can lead to thrombus formation and subsequent cardiovascular events. Using the test methods of Ma et al., additional dose-response studies with several statins and standard antiplatelet drugs are needed to confirm their effects on platelet aggregation, if any. Furthermore, we need to determine whether the antiplatelet effect of the statins, if present, is independent of their hypocholesterolemic action. The additional studies could provide important clues toward the development of new and specific antithrombotic drugs.